Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T36612 | Target Info | |||
| Target Name | Peptidyl arginine deiminase type III (PADI3) | ||||
| Synonyms | Protein-arginine deiminase type-3; Protein-arginine deiminase type III; Peptidylarginine deiminase III; PDI3; PAD3 | ||||
| Target Type | Literature-reported Target | ||||
| Gene Name | PADI3 | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: N-[(1s)-1-(Aminocarbonyl)-4-(Ethanimidoylamino)butyl]benzamide | Ligand Info | |||||
| Structure Description | Structure of the peptidylarginine deiminase type III (PAD3) in complex with Cl-amidine | PDB:7D56 | ||||
| Method | X-ray diffraction | Resolution | 3.17 Å | Mutation | No | [1] |
| PDB Sequence |
MSLQRIVRVS
10 LEHPTSAVCV20 AGVETLVDIY30 GSVPEGTEMF40 EVYGTPGVDI50 YISPNMERGR 60 ERADTRRWRF70 DATLEIIVVM80 NSPSNDLNDS90 HVQISYHSSH100 EPLPLAYAVL 110 YLTCVDISLD120 CDLNVDKRQW139 VWGPSGYGGI149 LLVNCDRDDP159 SCDVQDNCDQ 169 HVHCLQDLED179 MSVMVLRTQG189 PAALFDDHKL199 VLHTSSYDAK209 RAQVFHICGP 219 EDVCEAYRHV229 LGQDKVSYEV239 PRLHGDEERF249 FVEGLSFPDA259 GFTGLISFHV 269 TLLDDSASPI284 FTDTVVFRVA294 PWIMTPSTLP304 PLEVYVCRVR314 NNTCFVDAVA 324 ELARKAGCKL334 TICPQAENRW347 IQDEMELGYV357 QAPHKTLPVV367 FDSPRNGELQ 377 DFPYKRILGP387 DFGYVTREPR397 DSGLDSFGNL410 EVSPPVVANG420 KEYPLGRILI 430 GGNLPGRVTQ444 VVRDFLHAQK454 VQPPVELFVD464 WLAVGHVDEF474 LSFVPAPDGK 484 GFRMLLASPG494 ACFKLFQEKQ504 KCGHGRALLF514 QGVVDDEQVK524 TISINQVLSN 534 KDLINYNKFV544 QSCIDWNREV554 LKRELGLAEC564 DIIDIPQLFK574 TERKKATAFF 584 PDLVNMLVLG594 KHLGIPKPFG604 PIINGCCCLE614 EKVRSLLEPL624 GLHCTFIDDF 634 TPYHMLHGEV644 HCGTNVCRKP654 FSFKWWNMVP664
|
|||||
|
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Arch Biochem Biophys. 2021 Sep 15;708:108911. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.